

Maarten R Hillen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6943648/maarten-r-hillen-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

295
citations

10
h-index

16
g-index

27
ext. papers

438
ext. citations

5.7
avg, IF

3.15
L-index

#	Paper	IF	Citations
23	Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis. <i>Journal of Autoimmunity</i> , 2018 , 89, 162-170	15.5	48
22	Increased CCL25 and T Helper Cells Expressing CCR9 in the Salivary Glands of Patients With Primary Sjögren's Syndrome: Potential New Axis in Lymphoid Neogenesis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 2038-2051	9.5	32
21	Salivary Gland Pathology in Sjögren's Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2016 , 42, 473-83	2.4	26
20	Dendritic cells, T-cells and epithelial cells: a crucial interplay in immunopathology of primary Sjögren's syndrome. <i>Expert Review of Clinical Immunology</i> , 2014 , 10, 521-31	5.1	23
19	Plasmacytoid DCs From Patients With Sjögren's Syndrome Are Transcriptionally Primed for Enhanced Pro-inflammatory Cytokine Production. <i>Frontiers in Immunology</i> , 2019 , 10, 2096	8.4	21
18	High soluble IL-7 receptor expression in Sjögren's syndrome identifies patients with increased immunopathology and dryness. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1735-6	2.4	18
17	Leflunomide/Hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. <i>Lancet Rheumatology, The</i> , 2020 , 2, e260-e269	14.2	17
16	Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sjögren's syndrome. <i>European Journal of Immunology</i> , 2020 , 50, 119-129	6.1	16
15	Dysregulated miRNome of plasmacytoid dendritic cells from patients with Sjögren's syndrome is associated with processes at the centre of their function. <i>Rheumatology</i> , 2019 , 58, 2305-2314	3.9	12
14	Epigenetically quantified immune cells in salivary glands of Sjögren's syndrome patients: a novel tool that detects robust correlations of T follicular helper cells with immunopathology. <i>Rheumatology</i> , 2020 , 59, 335-343	3.9	11
13	Implication of miR-126 and miR-139-5p in Plasmacytoid Dendritic Cell Dysregulation in Systemic Sclerosis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	9
12	Salivary gland secretome: a novel tool towards molecular stratification of patients with primary Sjögren's syndrome and non-autoimmune sicca. <i>RMD Open</i> , 2019 , 5, e000772	5.9	8
11	Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren's syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?. <i>RMD Open</i> , 2019 , 5, e000701	5.9	7
10	Circulating small non-coding RNAs reflect IFN status and B cell hyperactivity in patients with primary Sjögren's syndrome. <i>PLoS ONE</i> , 2018 , 13, e0193157	3.7	7
9	MicroRNA-130a Contributes to Type-2 Classical DC-activation in Sjögren's Syndrome by Targeting Mitogen- and Stress-Activated Protein Kinase-1. <i>Frontiers in Immunology</i> , 2019 , 10, 1335	8.4	7
8	Towards standardisation of histopathological assessments of germinal centres and lymphoid structures in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e31	2.4	6
7	The Additive Inflammatory In Vivo and In Vitro Effects of IL-7 and TSLP in Arthritis Underscore the Therapeutic Rationale for Dual Blockade. <i>PLoS ONE</i> , 2015 , 10, e0130830	3.7	6

6	Decreased expression of thymic stromal lymphopoietin in salivary glands of patients with primary Sjögren's syndrome is associated with increased disease activity. <i>Modern Rheumatology</i> , 2016 , 26, 105-9	3.3	5
5	Thymic stromal lymphopoietin as a novel mediator amplifying immunopathology in rheumatic disease. <i>Rheumatology</i> , 2015 , 54, 1771-9	3.9	5
4	Autoantigen /Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren's syndrome is associated with B cell hyperactivity and type I interferon activity. <i>RMD Open</i> , 2020 , 6,	5.9	4
3	Galectin-9 reflects the interferon signature and correlates with disease activity in systemic autoimmune diseases. Response to: Biomarkers: to be or not to be by Yavuz and Rönblom. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e9	2.4	3
2	Targeting CD1c-expressing classical dendritic cells to prevent thymus and activation-regulated chemokine (TARC)-mediated T-cell chemotaxis in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2017 , 46, 11-16	1.9	2
1	The Transcriptomic Profile of Monocytes from Patients With Sjögren's Syndrome Is Associated With Inflammatory Parameters and Is Mimicked by Circulating Mediators. <i>Frontiers in Immunology</i> , 2021 , 12, 701656	8.4	1